Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin gets more time...

    Lupin gets more time from Government to complete Indore SEZ project

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-09T10:01:40+05:30  |  Updated On 9 May 2019 10:01 AM IST
    Lupin gets more time from Government to complete Indore SEZ project

    The decision to give more time to Lupin for the completion of its project was taken by the Board of Approval (BoA) in its meeting on April 22 here. BoA is an inter-ministerial body, headed by the Commerce Secretary.


    Mumbai: The government has approved a proposal of drug firm Lupin to take more time for completion of its project at Indore special economic zone (SEZ) with proposed investment of Rs 205.69 crore. The decision to give more time was taken by the Board of Approval (BoA) in its meeting on April 22 here. BoA is an inter-ministerial body, headed by the Commerce Secretary. It is the highest decision-making authority of SEZs.


    "The board, after deliberations, approved the extension of the validity of the LoP (letter of permission) up to April 11, 2020," the minutes of the BoA meeting said.


    Read Also: Indore SEZ project: Lupin seeks more time from Government to complete project


    The company is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations metered dose inhalers and dry powder inhalers.


    It has requested for extension of letter of permission (LoP) beyond April 11, 2019, for one year up to April 11, 2020.


    It had received the LoP on April 12, 2016, extended twice till April 11 this year.


    The development commissioner (DC) of Indore SEZ had recommended the company's request to BoA as the unit has made the expenditure of Rs 43.11 crore till March 28 and the construction activities are in full swing and, are expected to be completed by November 2019.


    The unit has expressed its commitment to commence production before March 2020.


    The company has stated that the delay in the appointment of land resulted in the delayed start of the project.


    As per the SEZ rules, DC is authorised to grant an extension of validity of LoP beyond the second year of the expiry of the original validity. However, it is subject to a condition that two-thirds of the activities including construction relating to setting up of the unit is complete and a chartered engineer's certificate to this effect is submitted by the entrepreneur.


    If these conditions are not met, then the unit has to approach the BoA for seeking more time.


    Further, the Board of Approval has granted in-principle to a proposal of L&T MBDA Missile Systems Ltd for setting up of an SEZ unit in Aspen Infrastructure Ltd for assembling, integration, functional testing of missile subsystems and missile weapon systems.


    Similarly, a proposal of Tata Power Company, SEZ unit under Cochin SEZ, for grant of industrial licence for manufacture of defence aircraft for military applications.

    assemblingBOABoard of ApprovalCochin SEZcommerce secretaryfunctional testing of missile subsystemsIndore SEZintegrationInvestmentL&T MBDA Missile Systemsletter of permissionLOPLupinmissile weapon systemsMumbaipharmaceuticalSEZSEZ rulesSpecial Economic ZoneTata Power Company SEZ
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok